Literature DB >> 28260149

Utility scores for different health states related to depression: individual participant data analysis.

Spyros Kolovos1, Judith E Bosmans2, Johanna M van Dongen2, Birre van Esveld2, Dorcas Magai3, Annemieke van Straten3, Christina van der Feltz-Cornelis4,5, Kirsten M van Steenbergen-Weijenburg6, Klaas M Huijbregts7, Harm van Marwijk8,9, Heleen Riper3, Maurits W van Tulder2.   

Abstract

OBJECTIVES: Depression is associated with considerable impairments in health-related quality-of-life. However, the relationship between different health states related to depression severity and utility scores is unclear. The aim of this study was to evaluate whether utility scores are different for various health states related to depression severity.
METHODS: We gathered individual participant data from ten randomized controlled trials evaluating depression treatments. The UK EQ-5D and SF-6D tariffs were used to generate utility scores. We defined five health states that were proposed from American Psychiatric Association and National Institute for Clinical Excellence guidelines: remission, minor depression, mild depression, moderate depression, and severe depression. We performed multilevel linear regression analysis.
RESULTS: We included 1629 participants in the analyses. The average EQ-5D utility scores for the five health states were 0.70 (95% CI 0.67-0.73) for remission, 0.62 (95% CI 0.58-0.65) for minor depression, 0.57 (95% CI 0.54-0.61) for mild depression, 0.52 (95%CI 0.49-0.56) for moderate depression, and 0.39 (95% CI 0.35-0.43) for severe depression. In comparison with the EQ-5D, the utility scores based on the SF-6D were similar for remission (EQ-5D = 0.70 vs. SF-6D = 0.69), but higher for severe depression (EQ-5D = 0.39 vs. SF-6D = 0.55).
CONCLUSIONS: We observed statistically significant differences in utility scores between depression health states. Individuals with less severe depressive symptoms had on average statistically significant higher utility scores than individuals suffering from more severe depressive symptomatology. In the present study, EQ-5D had a larger range of values as compared to SF-6D.

Entities:  

Keywords:  Depression; EQ-5D; Multilevel analysis; Quality-of-life; SF-6D; Utility scores

Mesh:

Year:  2017        PMID: 28260149      PMCID: PMC5486895          DOI: 10.1007/s11136-017-1536-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  64 in total

Review 1.  Health outcomes in economic evaluation: the QALY and utilities.

Authors:  Sarah J Whitehead; Shehzad Ali
Journal:  Br Med Bull       Date:  2010-10-29       Impact factor: 4.291

2.  Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom.

Authors:  Julieta Galante; Federico Augustovski; Lisandro Colantonio; Ariel Bardach; Joaquin Caporale; Sebastian Garcia Marti; Paul Kind
Journal:  Value Health       Date:  2011 Jul-Aug       Impact factor: 5.725

3.  Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders.

Authors:  Samuli I Saarni; Satu Viertiö; Jonna Perälä; Seppo Koskinen; Jouko Lönnqvist; Jaana Suvisaari
Journal:  Br J Psychiatry       Date:  2010-11       Impact factor: 9.319

4.  Measuring health-related utility: why the disparity between EQ-5D and SF-6D?

Authors:  Stirling Bryan; Louise Longworth
Journal:  Eur J Health Econ       Date:  2005-09

5.  Comparing SF-6D and EQ-5D utilities across groups differing in health status.

Authors:  Nick Kontodimopoulos; Evelina Pappa; Angelos A Papadopoulos; Yannis Tountas; Dimitris Niakas
Journal:  Qual Life Res       Date:  2008-11-29       Impact factor: 4.147

6.  Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis.

Authors:  Laura Manea; Simon Gilbody; Dean McMillan
Journal:  CMAJ       Date:  2011-12-19       Impact factor: 8.262

Review 7.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

8.  A comparison of the performance of the EQ-5D and SF-6D for individuals aged >or= 45 years.

Authors:  Garry R Barton; Tracey H Sach; Anthony J Avery; Claire Jenkinson; Michael Doherty; David K Whynes; Kenneth R Muir
Journal:  Health Econ       Date:  2008-07       Impact factor: 3.046

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Stepped care treatment for depression and anxiety in primary care. a randomized controlled trial.

Authors:  Wike Seekles; Annemieke van Straten; Aartjan Beekman; Harm van Marwijk; Pim Cuijpers
Journal:  Trials       Date:  2011-07-07       Impact factor: 2.279

View more
  6 in total

1.  Cost-effectiveness of a preferred intensity exercise programme for young people with depression compared with treatment as usual: an economic evaluation alongside a clinical trial in the UK.

Authors:  David Turner; Tim Carter; Tracey Sach; Boliang Guo; Patrick Callaghan
Journal:  BMJ Open       Date:  2017-11-26       Impact factor: 2.692

Review 2.  Cost effectiveness of guided Internet-based interventions for depression in comparison with control conditions: An individual-participant data meta-analysis.

Authors:  Spyros Kolovos; Johanna M van Dongen; Heleen Riper; Claudia Buntrock; Pim Cuijpers; David D Ebert; Anna S Geraedts; Robin M Kenter; Stephanie Nobis; Andrea Smith; Lisanne Warmerdam; Jill A Hayden; Maurits W van Tulder; Judith E Bosmans
Journal:  Depress Anxiety       Date:  2018-01-12       Impact factor: 6.505

3.  Five-year cost-effectiveness analysis of the European Fans in Training (EuroFIT) physical activity intervention for men versus no intervention.

Authors:  Spyros Kolovos; Aureliano P Finch; Hidde P van der Ploeg; Femke van Nassau; Hana M Broulikova; Agni Baka; Shaun Treweek; Cindy M Gray; Judith G M Jelsma; Christopher Bunn; Glyn C Roberts; Marlene N Silva; Jason M R Gill; Øystein Røynesdal; Willem van Mechelen; Eivind Andersen; Kate Hunt; Sally Wyke; Judith E Bosmans
Journal:  Int J Behav Nutr Phys Act       Date:  2020-03-04       Impact factor: 6.457

4.  Long-term outcomes in patients with severe depression after in-hospital treatment - study protocol of the depression long-term Augsburg (DELTA) study.

Authors:  Inge Kirchberger; Barbara Maleckar; Christine Meisinger; Jakob Linseisen; Max Schmauss; Jessica Baumgärtner
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

5.  Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.

Authors:  Carlo Lazzaro; Roberto Bergamaschi; Mauro Zaffaroni; Rocco Totaro; Damiano Paolicelli
Journal:  Neurol Sci       Date:  2022-04-14       Impact factor: 3.830

6.  Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study.

Authors:  Delphine Saragoussi; Michael Cronquist Christensen; Lene Hammer-Helmich; Benoît Rive; Maëlys Touya; Josep Maria Haro
Journal:  Neuropsychiatr Dis Treat       Date:  2018-05-22       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.